Results 71 to 80 of about 23,901 (228)

Denosumab discontinuation and fracture risk: getting the balance right

Internal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

, 2008
E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of ...
E Michael Lewiecki
core  

Should denosumab treatment for osteoporosis be continued indefinitely?

, 2021
Denosumab was approved for the treatment of postmenopausal osteoporosis in 2010, based on the FREEDOM study, which indicated a benefit in terms of increased bone mineral density and reduced risk of major osteoporotic fracture.
Malachi J. McKenna, McKenna, Malachi J, Jane A. Noble, Noble, Jane A, Crowley, Rachel K, Rachel K. Crowley   +5 more
core   +1 more source

Hypophosphataemia in adults: approach to diagnosis and management

Internal Medicine Journal, EarlyView.
Abstract Hypophosphataemia is a common electrolyte disorder which can have clinically significant consequences for bone, muscle, neurological and haematological function. Its causes range from transient transcellular shifts in hospitalised patients to chronic renal phosphate‐wasting disorders mediated by fibroblast growth factor 23 (FGF23).
Kajanan Parameshwaran, Mawson Wang, Kirtan Ganda   +2 more
wiley   +1 more source

Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study

International Journal of Nephrology, 2017
Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients.
Hiroya Takami, Kazunori Washio, Hiromichi Gotoh   +2 more
doaj   +1 more source

Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients

International Journal of Endocrinology, 2020
Purpose. Denosumab is a monoclonal antibody that prevents the development of osteoclasts. The effect of denosumab in solid organ transplant recipients has been elucidated, but its effect in haematopoietic stem cell transplantation recipients has not been
Chaiho Jeong, Hee-Je Kim, Seok Lee, Moo Il Kang, Jeonghoon Ha   +4 more
doaj   +1 more source

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

, 2009
Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density.
Kutilek, S, Eastell, Richard, ZOOG HP, Zanchetta J, Kutilek, S., Wang A, FREEDOM Trial, Zoog, H.B., Delmas, PD, FREEDOM, Trial, Siddhanti S, Nuti R, Delmas, P., Wang, A., McClung MR, San Martin J, Cummings, Steven R, Siddhanti, S, Christiansen, C, Eastell, R., Siris, E.S., Zanchetta, Jose, Libanati, C., Austin, Matt, Adami, Silvano, Siris, Ethel S, Reid, Ian R, Adami, S., Zoog HB, McClung, MR, Siris, ES, Kutilek S, Cummings, S.R., Martin, JS, Delmas, Pierre, Libanati C, Cummings, SR, Austin, M., Zanchetta, J, Libanati, Cesar, Devogelaer, Jean-Pierre, McClung, Michael R, Libanati, C, Eastell, R, Christiansen C, Reid, I.R., Wang, A, Wang, Andrea, San Martin, Javier, Reid IR, Christiansen, C., Zoog, Holly B, Adami, S, Christiansen, Claus, Delmas P, Siris ES, Austin, M, Kutilek, Stepan, San, Martin J, MINISOLA, Salvatore, Cummings SR, Adami S, Austin M, Reid, IR, San Martin, J., Siddhanti, Suresh, McClung, M.R., Delmas, P, Siddhanti, S., Zoog, HB, Eastell R, Zanchetta, J., Austin, MD, Lippuner, Kurt   +73 more
core   +1 more source

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis

Bone Reports, 2017
Denosumab, a human monoclonal antibody against RANK ligand, is shown to have strong anti-fracture effects in Japanese osteoporosis patients. However, there have been no data showing actions on Japanese bone architecture.
Teruki Sone, Naohiro Kon, Kenneth W. Gaither, Naoki Okubo, Taisuke Osakabe, Yutaka Nakayama, Masao Fukunaga, Masako Ito, Toshitaka Nakamura   +8 more
doaj   +1 more source

Giant cell tumor of a rib following denosumab treatment

, 2018
Giant cell tumor (GCT) of the bone is an aggressive lytic lesion, commonly treated with surgery. Denosumab is a relatively recently introduced osteoclast activation inhibitor used for neoadjuvant therapy of GCT.
John Kosiuk, Alexandre Semionov
core   +1 more source

Modified Osseodensification Bur (Sun Bur) for Transcrestal Sinus Floor Elevation With 2–6 mm Residual Bone Height: A Retrospective Cohort Study

Journal of Esthetic and Restorative Dentistry, EarlyView.
ABSTRACT Objective To evaluate the clinical efficacy of a modified osseodensification (OD) bur for transcrestal sinus floor elevation (tSFE) and to compare clinical outcomes between patients with residual bone height (RBH) of 2–< 4 mm (Group A) and 4–6 mm (Group B).
Mingxu Sun, Xian Ding, Zhaozhao Chen, Chongxia Yue, Hom‐Lay Wang   +4 more
wiley   +1 more source